Top Markets
#1 Trillions Trillions +4,371.27%
#2 Ozapay Ozapay +38.46%
#3 UnifAI Network UnifAI Network +23.35%
#4 Aria.AI Aria.AI +22.13%
#5 Zano Zano +17.76%
#6 Osaka Protocol Osaka Protocol +14.37%
#7 StakeStone StakeStone +14.34%
#8 Vestra DAO Vestra DAO +12.12%
#9 River Pts River Pts +10.84%
#10 Janction Janction +10.23%
Coin of the day
Trillions Trillions
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Kedudukan dalam Saham #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Harga Saham
$0.28545656
Modal Pasaran
$4.50M
Perubahan (1 hari)
5.97%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Acticor Biotech SAS (ALACT)

Kategori

Healthcare
Pendapatan untuk Acticor Biotech SAS (ALACT)
Pendapatan pada Jun 2024 TTM: $-12.93M
Menurut laporan kewangan terkini Acticor Biotech SAS, pendapatan semasa syarikat ialah $-12.93M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-19.33M, penurunan berbanding pendapatan pada tahun 2021 yang berjumlah $-16.54M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Acticor Biotech SAS dari 2010 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -158,354.90%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -36,019.43%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -40,564.29%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -16,637.04%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -12,587.97%
AU